Our potential impact is beyond measure
We are committed to the discovery and development of a transformational generation of targeted therapies for women’s cancers. Led by a team of professionals with a deep understanding of endocrine-driven cancers and extensive development expertise, we are persistent in our pursuit of advancing the standard of care for women living with cancer.
Our Team
leadership
board of directors
leadership
board of directors
leadership
Sean P. Bohen, M.D., Ph.D.
President and CEO
Shane Kovacs
Chief Operating and Financial Officer
Naseem Zojwalla, M.D.
Chief Medical Officer
David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Julie Dexter
Senior Vice President and Head of People
Sasha Austin, CPA
Vice President, Finance and Controller
Demiana Faltaos, PharmD, Ph.D.
Vice President, Head of Clinical Pharmacology
Richard Hernandez
Vice President, Clinical Development Operations
Kamesh Kuchimanchi, Ph.D.
Vice President, Regulatory Affairs and Quality Assurance
Kristin Lanzi
Vice President, Information Technology
Gopinath Palanisamy, DVM, Ph.D., DACVP
Vice President, Pre-Clinical Pharmacology and Toxicology
Mark Shilkrut, M.D., Ph.D.
Vice President, Clinical Development
Margaret Tonda, PharmD
Vice President, Clinical Science
Rachel Wei, Ph.D.
Vice President, Biostatistics
Jim Zhang, Ph.D.
Vice President, CMC
Yolande Du Toit, MD
Vice President, Medical Affairs
Sean P. Bohen, M.D., Ph.D.
President and CEO
Ian Clark
Chairman of the Board
Cindy Butitta
Member
Scott Garland
Member
Cyrus Harmon, Ph.D.
Member
Sandra J. Horning, M.D., FACP, FASCO
Member
Gorjan Hrustanovic, Ph.D.
Member
Yi Larson, MBA
Member
Andy Rappaport
Member
Graham Walmsley, M.D., Ph.D.
Member